Entries by Peggy Bickerton

Astex Pharmaceuticals Presents Overall Survival Data From ASCERTAIN Phase 3 Study of Oral Hypomethylating Agent INQOVI® (decitabine and cedazuridine) in MDS and CMML at International Congress on Myelodysplastic Syndromes

Study achieved median overall survival of 31.7 months Updated efficacy data demonstrated an overall response rate of 62%, with 22% of patients achieving a complete response INQOVI is the only oral hypomethylating agent with equivalent exposure to its intravenous (IV) form Pleasanton, CA, September 23, 2021. Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka […]

NCCN Announces Projects to Study Oral Decitabine and Cedazuridine in Collaboration with Taiho Oncology

For Immediate Release: April 14, 2021Media Contact:Rachel Darwin267-622-6624darwin@nccn.org NCCN Oncology Research Program to oversee projects exploring oral medication combination targeting tumor suppression genes. PLYMOUTH MEETING, PA [April 14, 2021] — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced that three projects have been selected to study oral decitabine (35 mg) and […]